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Neurobiology of Disease
Anti-Inflammatory Modulation of Microglia via
CD163-Targeted Glucocorticoids Protects Dopaminergic
Neurons in the 6-OHDA Parkinson’s Disease Model
XNoemie Tentillier,1,2 XAnders Etzerodt,2 XMads N. Olesen,1,2 F. Sila Rizalar,1,2 XJan Jacobsen,3 XDirk Bender,3
XSøren K. Moestrup,2,4 and XMarina Romero-Ramos1,2
1CNS Disease Modeling Group, NEURODIN, 2Department of Biomedicine, and 3Department of Clinical Medicine, PET Center, Aarhus University Hospital,
DK-8000 Aarhus C, Denmark, and 4Department of Cancer and Inflammation Research, Syddansk University, DK-5000 Odense, Denmark
Increasing evidence supports adecisive role for inflammation in theneurodegenerativeprocess ofParkinson’sdisease (PD).The immune
response in PD seems to involve, not only microglia, but also other immune cells infiltrated into the brain. Indeed, we observed here the
infiltrationofmacrophages, specificallyCD163macrophages, into theareaofneurodegeneration in the6-hydroxydopamine (6-OHDA)
PDmodel. Therefore,we investigated the therapeutic potential of the infiltratedCD163macrophages tomodulate localmicroglia in the
brain to achieve neuroprotection. To do so, we designed liposomes targeted for the CD163 receptor to deliver dexamethasone (Dexa) into
the CD163macrophages in the 6-OHDAPDmodel. Our data show that a fraction of the CD163-targeted liposomeswere carried into the
brain after peripheral intravenous injection. The 6-OHDA-lesioned rats that received repeated intravenous CD163-targeted liposomes
with Dexa for 3 weeks exhibited better motor performance than the control groups and had minimal glucocorticoid-driven side effects.
Furthermore, these animals showed better survival of dopaminergic neurons in substantia nigra and an increased number of microglia
expressingmajor histocompatibility complex II. Therefore, rats receiving CD163-targeted liposomes with Dexa were partially protected
against 6-OHDA-induced dopaminergic neurodegeneration, which correlatedwith a distinctivemicroglia response. Altogether, our data
support theuse ofmacrophages for themodulationof brainneurodegeneration and specifically highlight thepotential of CD163-targeted
liposomes as a therapeutic tool in PD.
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Introduction
Parkinson’s disease (PD) is characterized by the progressive loss
of dopaminergic neurons in the substantia nigra (SN) and the
presence of intraneuronal aggregated -synuclein in the Lewy
bodies. It has been proposed that the immune system plays an
active part in the symptoms and progression of PD (Doorn et al.,
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Significance Statement
The immune response now evident in the progression of Parkinson’s disease comprises both local microglia and other immune
cells. We provide evidence that CD163macrophages can be a target to modulate brain immune response to achieve neuropro-
tection in the 6-hydroxydopamine model. To do so, we targeted the CD163 population, which to a low but significant extent
infiltrated in the neurodegenerating area of the brain. Specially designed liposomes targeted for the CD163 receptor were loaded
with glucocorticoids and injected peripherally to modify the infiltrated CD163 cells toward an anti-inflammatory profile. This
modification of the CD163 population resulted in a distinctive microglial response that correlated with decreased dopaminergic
cell death and better motor performance.
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2012; Blandini, 2013). Supporting this, epidemiological studies
show that the use of nonaspirin NSAIDs decreases the risk of
developing PD (Rees et al., 2011) and genetic studies described a
significant association between polymorphisms in the HLA gene
loci and the risk for late-onset PD (Hamza et al., 2010; Interna-
tional Parkinson Disease Genomics Consortium, 2011).
Microgliosis in PD brain has been shown repeatedly in pa-
tients and has also been observed in animal models of PD (Ce-
bria´n et al., 2015). PET brain imaging and postmortem studies in
PD shows early but sustained microglia activation that was not
only limited to areas with significant neuronal death, but was also
correlated with -synuclein pathology (Hunot et al., 1996; Knott
et al., 2000; Imamura et al., 2003; Croisier et al., 2005; Ouchi et al.,
2005; Gerhard et al., 2006). Importantly, -synuclein released
from neurons acts as a proinflammogen on microglia, further
contributing to the microgliosis (Sanchez-Guajardo et al.,
2013a). The microglia response is complex, as shown by the va-
riety of proteins upregulated, such as MHC-II, CD68 (Banati et
al., 1998; Croisier et al., 2005), COX2, and iNOS (Hunot et al.,
1996; Knott et al., 2000). The immune response is also noticed in
periphery and involves both pro-inflammatory signals such as
TNF and IL-1b, but also anti-inflammatory molecules such as
IL-4 and IL-10, all of which are increased in the serum and/or CSF
of PD patients (Mogi et al., 1994; Garcia-Esparcia et al., 2014).
This widespread and chronic inflammatory reaction in PD pa-
tients suggests that microglia fail to solve the insult that triggers
their activation and such maintained chronic activation might
lead to neuronal death (Herrera et al., 2005; Joers et al., 2016).
The immune response in PD patients and in animal PD mod-
els seems to involve, not only microglia, but also infiltrated pe-
ripheral macrophages (Zhao et al., 2011) and lymphocytes
(Lossinsky and Shivers, 2004; Brochard et al., 2009). It has been
proposed that CD4 T cells may play a key role in the dopaminer-
gic cell death in the MPTP and the -synuclein PD models (Bro-
chard et al., 2009; Sanchez-Guajardo et al., 2013b). Further
supporting a role of peripheral cells, unrelated inflammatory pe-
ripheral events increase neurodegeneration in PD models (Vil-
laran et al., 2010; Gao et al., 2011).
Synthetic glucocorticoids are the most potent known drugs
used to relieve inflammation. Among them, dexamethasone
(Dexa) was shown previously to be neuroprotective in the MPTP
mouse PD model (Kurkowska-Jastrzebska et al., 2004) and in an
LPS rat PD model (Castan˜o et al., 2002). However, chronic treat-
ment with Dexa and glucocorticoids are well known to induce
serious side effects, so we used a low-dose Dexa-targeted ap-
proach. We have shown previously that both in vitro and in vivo,
anti-CD163-Dexa-conjugate attenuated the LPS-induced in-
flammatory response in rats (Graversen et al., 2012). CD163 is a
hemoglobin scavenger receptor (Kristiansen et al., 2001) ex-
pressed in monocytes/macrophages that has been involved in
different inflammatory diseases (Etzerodt and Moestrup, 2013;
Dultz et al., 2016; Liu et al., 2015). In the brain, CD163 is ex-
pressed in perivascular macrophages (PVMs) but not in micro-
glia, so it constitutes a potential marker for infiltrated peripheral
immune cells in the brain parenchyma (Polfliet et al., 2006).
Microgliosis and increased pro-inflammatory mediators in
brain are also found in the 6-hydroxydopamine (6-OHDA) PD
model (Cicchetti et al., 2002; Nagatsu and Sawada, 2005; McCoy
et al., 2006; Na et al., 2010). In the present study, we investigated
macrophage infiltration in the brains of 6-OHDA-lesioned rats
and tested whether anti-inflammatory modulation of infiltrating
macrophages protects against neurodegeneration.
Materials andMethods
Animals. Adult female Sprague Dawley rats (n 120; Taconic) weighing
225–250 g at the time of the surgery were housed two per cage with ad
libitum access to food and water in a climate-controlled facility under
12:12 h light/dark cycle. The animal experiments were conducted under
humane conditions with ethical approval from the Danish Animal In-
spectorate that adheres to the European Rules.
Dopaminergic lesion. Rats were anesthetized with medetomidine hy-
drochloride (1 mg/ml) diluted 1/15 in fentanyl (50 g/ml) (1.6 –1.8 ml/
injection, i.p.) and placed in a stereotaxic apparatus (Stoeling). The skull
was exposed by an incision in the midline and three 2 mm holes were
drilled to allow 2 l injections of 6-OHDA (7 g in saline and 0.02%
ascorbic acid) per site or vehicle for sham injections. The solution was
injected over 2.5 min using a 5 l Hamilton syringe attached to a glass
capillary (outer diameter of 60 – 80 m) at the following coordinates (in
mm): AP 1.0; 0,0; 1.0 and ML 3.0; 3.4; 4.2 from bregma and
4.9 ventral from dura (nose bar at 3.3) according to the atlas of
Paxinos and Watson (Paxinos and Watson, 1998). After the injection, the
cannula was left in place for 5 min before slow retraction. Animals were
sutured using metal clips and injected with buprenorphine (0.36 mg/kg)
for pain relief and awakened with a single injection of antipamezole
hydrochloride (0.7 mg/kg). Fully awakened animals were placed back in
their cages.
The 6-OHDA (Sigma-Aldrich) was dissolved at 4.2 mg/ml (the
6-OHDA used contains 82% free base) with 0.02% ascorbic acid in sterile
saline, kept on ice for no more than 2 h, and protected from light
throughout the entire procedure. For sham injections, 0.02% ascorbic
acid in sterile saline was used.
Liposome preparation. Liposomes were prepared and modified for
CD163 targeting as described previously (Etzerodt et al., 2012). In short,
liposome formulations were formed using the ethanol injection method
from a mixture of hematopoietic stem/progenitor cells Hydrogenated
soy L--phosphatidylcholine, cholesterol, and mPEG2000-PE (molar
ratio of 55:40:5; Lipoid and Sigma-Aldrich). Lipids were dissolved in 100
l of EtOH at 65°C for 10 min, followed by hydration for 1 h at 65°C in
900 l of aqueous buffer. Liposomes were sized by extrusion 25 times
through a 0.1 m filter using a mini-extruder kit (Avanti Polar Lipids)
and dialyzed against 150 mM NaCl (0.9% NaCl) overnight at 4°C. Lipid
content, drug content, and encapsulation efficiency were estimated from
high-pressure size-exclusion chromatography (UV absorbance 210 nm)
using a Dionex UltiMate 3000 HPLC system (Thermo Scientific)
equipped with an Ascentis C18 column (Sigma-Aldrich). Liposome sizes
were estimated using dynamic light scattering and the DynaPro NanoS-
tar system (Wyatt Technology). Modification of liposomes for CD163
targeting was done as described previously by the postinsertion method
of lipidated antibody using the CD163-antibody clone ED2 (AbD Sero-
tec) (Torchilin et al., 2001; Etzerodt et al., 2012).
For liposomes encapsulating calcein, lipids were rehydrated in 250 mM
calcein disodium (Sigma Aldrich) and 150 mM NaCl and dialysis was
repeated five times to remove excess calcein. Liposomes encapsulating
Dexa-21-hemisuccinate lipids were rehydrated in 200 mM CaAcO2 and
remote loading of Dexa was done using the remote loading technique for
amphiphatic weak acids (Clerc and Barenholz, 1995) with a Dexa to lipid
ratio of 1:10 (mol/mol). Formulation of liposomes encapsulating 125I-
labeled Bolton–Hunter reagent was done by rehydrating lipids in a 80 mM
HBS buffer (80 mM HEPES, 150 mM NaCl), pH 8.6, supplemented with
80 mM L-arginine (Mougin-Degraef et al., 2006). On the day of injection,
L-arginine-containing liposomes were radioactively labeled by incubat-
ing liposomes for 30 min at room temperature with 125I-Bolton–Hunter
reagent (0.48 MBq/mol lipid) in 5 mM CBS (5 mM citrate, pH 5.0, 150
mM NaCl). Excess 125I–Bolton–Hunter reagent was subsequently re-
moved using a Zeba Spin desalting column (7 K MWCO; Thermo Fisher
Scientific).
Biodistribution of radioactive CD163 liposomes. Three weeks after stri-
atal injections, 6-OHDA or sham (n  4 per group) rats were anesthe-
tized with 2.5% isoflurane (IsoVet 1000 mg/g inhalation vapor, liquid;
Chanelle) in 0.4 L/min O2 and 1 L/min N2O that was maintained during
the intraveous injections. A single intravenous, 0.5 ml injection of 125I-
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anti-CD163-liposomes (0.125 mM liposome solution, 1.5  10 6 cpm/
animal, n  8) was administered to each animal. Blood samples were
collected from the sublingual vein at several time points after liposome
injection (2, 20, 40, and 60 min). Rats were killed after 2 h by cervical
dislocation under anesthesia, at which time a final intracardiac blood
sample was taken and selected organs were rapidly dissected (heart, two
distant pieces of the spleen, liver, and both kidneys), weighed, and ana-
lyzed for 125I radioactivity using an alpha-counter (COBRA 5002;
PerkinElmer). The radioactivity results were adjusted to the mass of
tissue and are presented as a percentage of the total injected dose for each
organ. Time course of the blood clearance of 125I was determined in 0.5
ml of blood and is presented as relative radioactive emission compared
with emission 2 min after 125I-anti-CD163 injection.
Tracking of peripherally injected liposomes. One and 3 weeks after surgery
(6-OHDA; n 4 and sham; n 2), lesioned and naive (n 2) rats received
a single intravenous injection of CD163-targeted calcein-loaded liposomes
(ED2-LCL-Calcein; dose lipid 1.25 mM and IgG 0.075 mg/ml, injection
volume 2 ml/kg) under isoflurane anesthesia (same procedure as above).
Eighteen hours after ED2-LCL-Calcein injection, all animals were killed and
their brains perfused, sliced, and processed for immunofluorescence to de-
tect the presence of calcein in CD11b cells (see below).
Isolation of peritoneal macrophages, selection, and ex vivo loading. Peri-
toneal macrophages were collected from 8- to 10-week-old naive rats by
repeated PBS peritoneal lavage. The cell suspension obtained was centri-
fuged for 10 min at 300 g, the supernatant discarded, and the cell pellet
resuspended in RPMI (RPMI 1640 w/L-glutamine medium, Lonza) com-
plete medium (RPMI-CM: 10% heat-inactivated FCS; Thermo Fisher
Scientific) and 1% HEPES (Invitrogen). Cells were stained and processed
for FACS sorting of the CD11b/CD163 population with FACSAria
III sorters (BD Biosciences). Thereafter, the cells were briefly kept in
complete RPMI 1640 (Lonza) medium containing penicillin (100 U/ml;
Thermo Fisher Scientific)/streptomycin (100 U/ml; Thermo Fisher Sci-
entific) and 10% FCS (Thermo Fisher Scientific) at 37°C and 5% CO2
until proceeding with Qdot loading and in vivo injection.
Sorted CD11b/CD163 peritoneal macrophages were loaded with flu-
orescent Qdot565 following the protocol from the Qtracker565 cell-labeling
kit provided by the manufacturer (Thermo Fisher Scientific). Briefly, 10 nM
labeling solution was prepared from premixed solutions and incubated for 5
min at room temperature. Then, fresh complete RPMI was added to the
solution and vortexed for 30 s. Thereafter, a sample containing 106 cells
(from a cell suspension at 1  107 cells/ml in RPMI) was added to the
labeling solution and incubated for 45 min at 37°C, followed by 2 washes
with complete RPMI. The resulted cell suspension was maintained at room
temperature until being injected into the animals.
Flow cytometry. Freshly isolated cells were processed for flow cytometry
analysis within 2 h after the harvesting time. All incubations were performed
on ice and all washes (100l, 300 g, 5 min, 4°C) and antibody mixing were
done in FACS buffer (1% FCS; 5% EDTA, 50 mM; Sigma-Aldrich); 1%
penicillin/streptomycin (Invitrogen), in 1 PBS (Invitrogen). Cell number
and viability were assessed using cell counter (Moxi, Z Mini automated cell
counter; Orflo). Then 2 106/100 l cell suspensions were distributed in
Trucount Tubes (BD Biosciences) and washed twice. The cells were then
blocked for 10 min in 5% BSA in FACS buffer, washed afterward, and stained
with single antibody or antibody solution for 10 min in the dark using
CD11b-FITC (Clone OX-42; AbD Serotec) and CD163-AF647 (Clone ED2;
AbD Serotec). The optimal concentration of each antibody was determined
by titration in preliminary experiments. For each sample, we included un-
stained cells for negative controls and each antibody’s respective isotype
control. Thereafter, cells were washed twice and kept in FACS buffer for
analysis. Sample data and cell sorting were processed with FACSAria III
sorters (BD Biosciences). All samples were gated first on live cells according
to their forward scatter (FSC)/side scatter (SSC) and doublets were removed
by plotting data for height (H) and area (A): FSC-H/FSC-A and SSC-H/
SSC-A. After cell sorting, cells were collected in 50% FCS in PBS.
CD163-targeted Dexa-loaded liposome treatment. The rats were divided
into four groups, all receiving the first treatment injection in tail vein 1 d
before brain surgery, followed by three weekly injections for 3 weeks. The
experimental group of animals received 0.02 mg Dexa/kg encapsulated in
liposomes coated with anti-CD163-antibody (referred to hereafter as ED2-
LCL-Dexa). In addition, control groups included: (1) rats receiving PBS in
nontargeted liposomes (lipid dose: 0.125 mM, referred to as: Lip-PBS); (2)
rats receiving free Dexa (1.0 mg Dexa/kg, standard high dose according to
the literature; Graversen et al., 2012); and (3) rats receiving Dexa encapsu-
lated in nontargeted liposomes (0.02 mg Dexa/kg, referred to hereafter as
LCL-Dexa). For all injections, the rats were briefly anesthetized with 2.5%
isoflurane mixed with 0.4 L/min O2 and 1 L/min N2O and liposome prepa-
rations were injected slowly through the tail vein at a volume of 2 ml/kg
animal body weight.
Behavioral test. In the second week after striatal lesion, locomotor
asymmetry was evaluated using a modified version of the cylinder test
originally described (Schallert et al., 2000). Briefly, the animals are placed
in a transparent Plexiglas cylinder (height 30 cm, diameter 20 cm), with
two mirrors placed behind to visualize the cylinder surface fully. Spon-
taneous use of the animal forepaws (independently or simultaneously)
was video recorded and a total of 20 forepaw touches were counted. Each
animal was coded so that the researcher analyzing the video was blinded
to the identity of the animal. The animals were tested only once and, after
2–10 min inside the cylinder, were required to achieve the desired num-
ber of touches. The left paw touches were expressed as a percentage of
total forelimb touches. For data quality, a second observer scored a ran-
dom sample of 20% of the animals and the data between the two observ-
ers were compared for variability (Pearson r  0.081). In addition, an
unrelated researcher verified the accuracy of data transfer from the lab-
oratory notebooks to the electronic files.
Perfusion and tissue processing. Rats were killed 1 and 3 weeks after
surgery with an overdose of pentobarbital (50 mg/kg, i.p.). On respira-
tory arrest, they were perfused through the ascending aorta with ice-cold
saline, followed by 4% ice-cold paraformaldehyde (PFA; in 0.1 M NaPB,
pH 7.4). When relevant and before PFA perfusion, blood was collected
and the heart, thymus, liver, and/or spleen were dissected and frozen in
dry ice for storage at80°C. PFA-perfused brains were postfixed in the
same PFA solution for 2 h, transferred to 25% sucrose solution (in 0.02 M
NaPB), sliced into 40-m-thick coronal sections (Microm HM 450;
Brock and Michelsen), separated in serial sections (series of 8 for the
striatum and 6 for the SN), stored at20°C.
For selected experiments, animals were deeply anesthetized using iso-
flurane and killed by cervical dislocation. Thereafter, selected organs
were dissected, frozen in dry ice, and kept at80°C until use.
Immunohistochemistry. Immunohistochemical stainings were per-
formed on free-floating brain sections as described previously (Febbraro
et al., 2013) using the following mouse primary antibodies: tyrosine hy-
droxylase (TH; 1:3000; Millipore), CD11b (Mac1; 1:500; AbD Serotec),
CD163 (ED2; 1:1000; AbD Serotec), CD68 (ED1; 1:200; AbD Serotec),
and MHCII (OX-6; 1:250; AbD Serotec). The sections stained with
CD11b antibody were counterstained with cresyl violet (0.5% solution)
before coverslipping. Bright-field images were acquired with a Leica
DMI600B microscope.
For immunofluorescence, CD11b (Mac1; 1:500; AbD Serotec) pri-
mary antibody incubation was followed by several washes and incubated
with species-specific fluorophore-conjugated antibodies (Alexa-Fluor
647 and Alexa-Fluor 568; Invitrogen) in 0.25% Triton X-100 in KPBS
with 2.5% horse serum at room temperature for 2 h and DAPI (1: 2000;
Sigma-Aldrich) was added for the last 10 min for nuclear staining. After
final washes, sections were mounted and confocal images were obtained
using an LSM 710 Meta confocal microscope (Zeiss) with a 63 lens.
Microscopic analysis and stereological analysis. The unbiased stereologi-
cal estimation of the total number of either TH or CD11b cells in the
SN or CD163 cells in the striatum were made by an observer blinded to
the identity of the animal using the optical fractionator principle
(Westermeyer, 1991). This sampling technique is not affected by tissue
volume changes and does not require reference volume determinations.
Samplings were performed using the NewCast module in VIS software
(Visiopharm). A 1.25 low-power objective on a Leica DMI600B micro-
scope was used to delineate the borders of the SN and striatum based on
anatomical morphology. In brief, for the SN cells, every sixth section
from the entire SN (typically eight to nine sections in a series per animal),
from the rostral tip of the pars compacta to the caudal end of the pars
reticulate, was used. For striatum cells, every eighth section from the
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entire striatum (typically 10 –12 sections in a series per animal), from the
rostral tip of the striatum to the level of 1.80 relative to bregma, were
used. The actual counting was performed with a 40 objective (numer-
ical aperture 0.75). The counting frame (56.89 m  42.66 m) was
placed randomly by the VIS module and moved systematically until the
entire delineated region was sampled. The sampling frequency was cho-
sen by adjusting theX–Y step length between 190 and 240m for CD163
cell counting, between 230 and 280 for CD11b cell counting, and be-
tween 140 and 280 for TH cell counting such that between 100 and 200
cells were counted on each side of the brain for every animal. The esti-
mated total number of positive cells was calculated according to the
optical fractionator formula and a coefficient of error of 0.10 was
accepted.
For MHCII cell counting, one section of the SN from each animal
located between 5.60 mm and 6.04 mm from bregma according to
the mouse brain atlas (Paxinos and Watson, 1998) was selected and the
quantification was made using a bright-field Leica DMI600B microscope
at a magnification of 10.
Striatal fiber densitymeasurement. The optical density of TH fibers in
the striatum was measured at 6 different rostro-caudal levels according to
the rat brain atlas (Paxinos and Watson, 1998): AP:1.60;1.00; 0.20;
0.30;0.92;1.40 mm relative to bregma. The different brain sections
were scanned using a densitometer (Bio-Rad GS-710) and the digital
images obtained were analyzed by ImageJ software using grayscale. The
optical density for each section was corrected for nonspecific background
measured from corpus callosum. The data are presented as a percentage
of the lesioned side to the intact control side.
Analysis of cortisol levels. Sera were obtained from the collected blood
samples by centrifugation 400 g for 15 min at 4°C and the cortisol assay
was performed using 1:20 diluted samples. The endogenous cortisol con-
centrations were measured using the Cortisol Parameter Assay Kit (R&D
Systems). Sample dilutions were performed by adding 20 l of serum
sample into 380 l of calibrator diluent from the kit. The samples were
read using a Cobas 6000 analyzer (Roche Diagnostics) with 450 nm wave-
lengths according to the manufacturer’s instructions.
High-performance liquid chromatography. At the day of the analysis
frozen SN or striata were briefly sonicated (Branson Sonifer 250) on ice in
20 mM Tris-acetate (pH 6.1, 0.05 ml for each 0.01 g tissue weight). Then,
100 l of tissue homogenate was mixed 1:1 with 0.8 M perchloric acid,
incubated on ice for 15 min, diluted with Milli-Q water (Millipore), and
centrifuged at 10,600 g for 10 min at 4°C) through a filter with a 0.22
m pore size (Sigma-Aldrich). Finally, the supernatant was distributed
into vials and used for HPLC analysis. The concentrations of dopamine
(DA) and its metabolites, DOPAC, HVA, and 3-MT, were determined
via HPLC with electrochemical detection. Briefly, 75 l of sample was
injected automatically into the HPLC system and monoamines were
separated using a constant flow of 0.5 ml/min by reversed-phase chro-
matography (MD-150, C18), 150  2 mm (3 m) column (ESA no.
70 – 4129), using 90 mM sodium dihydrogen phosphate, 14.3 mM trieth-
ylamine, 1.7 nM sodium 1-octanesulphonic acid, 50 M EDTA and 10%
acetronitril, pH 3.0, as a mobile phase. Electrochemical detection was
accomplished using a coulometric analytical cell (ESA 5014B) and cell
potential set at E2  250 mV (Coulochem II; ESA). The standard
mixture of DA, DOPAC, HVA, and 3-MT was used to identify and quan-
tify each compounds from the animal samples. The final concentration
of each monoamine was adjusted to the protein concentration per sam-
ple. The protein concentration was determined by bicinchoninic acid
assay (BCA). A total of 50 l of the initial sonicated striatum and SN
samples was added to 96-well plate as triplicates. Standards prepared
with 0.02% BSA and ddH2O were also added as triplicates. A total of 200
l of the bicinchoninic acid/copper sulfate mixture (200 l of bicin-
choninic acid 4 l of copper sulfate per well) was added to each well.
After the Parafilm-sealed plate was incubated for 1 h at 37°C, protein
concentrations were determined using the Protein-Quant (BCA) pro-
gram in Softmax-Pro Software.
Statistics. In all cases, and when the experimental design allowed, the re-
searcher was blinded to the identity of the animal/sample handled or quan-
tified. All data were expressed as meanSEM. Statistical analyses were made
using GraphPad Prism 6.0 for Mac using one-way ANOVA test followed by
Tukey’s multiple-comparisons test. When appropriate, paired t tests were
used. Values of p 0.05 were considered to be significant.
Results
6-OHDA induced degeneration results in the increase of
CD163 cells in striatal parenchyma
The expression of the scavenger receptor CD163 in the brain is lim-
ited to meningeal macrophages and the PVM (Polfliet et al., 2006).
Therefore, the presence of CD163 cells in the brain parenchyma
may suggest an infiltration of peripheral, meningeal, or PVM cells or
an abnormal upregulation of the CD163 expression by the local
microglia. To determine whether the CD163 population changed
during the neurodegenerative process occurring in the 6-OHDA rat
PD model, we performed stereological quantification of the
CD163 cells in the striatum at 1 and 3 weeks after 6-OHDA sur-
gery. To account for the possible infiltration of CD163 cells into
the striatal parenchyma due to the physical damage induced by the
surgery, we performed a sham surgery in the contralateral side.
CD163 immunostaining revealed two types of cells: rod cells, which
were elongated and typically associated with blood vessels and thus
resemble the previously described PVMs (Fig. 1A	,B	), and polygo-
nal cells that were not associated with blood vessels but located in the
parenchyma and consequently might correspond to infiltrating
macrophages (Fig. 1B		,B			). One-week after surgery, no significant
changes in the total number of CD163cells were observed between
the ipsilateral and contralateral striatum. In the ipsilateral sham
striatum,
95% of the CD163 cells were found mainly as rod cells
(PVMs) that were clearly associated with blood vessels (Fig. 1B,C).
Similar results were obtained from the contralateral striata, although
with lower numbers of polygonal cells, suggesting a small but non-
significant increase of CD163 polygonal cells in the ipsilateral
striatum. However, 3 weeks after surgery and 6-OHDA injection, the
total number of CD163 cells was significantly increased in the
6-OHDA lesion striatum (Fig. 1C). This increase was due to an ele-
vated number of CD163 polygonal cells located in the striatal pa-
renchyma compared with the sham contralateral side (22% of total
CD163 cells), suggesting a recruitment of peripheral immune cells
to the side of neurodegeneration.
Peripherally transferred CD163 cells infiltrate the striatal
parenchyma in the 6-OHDA PD model
The stereological data suggest that the CD163 polygonal cell pop-
ulation is recruited to the brain, specifically to the striatum, upon
induction of neurodegeneration using 6-OHDA. To confirm that
peripheral CD163macrophages could be indeed recruited to the
brain parenchyma, CD11b/CD163peritoneal cells were isolated
from a group of naive rats (Fig. 2B,C) labeled with fluorescent Qdot
(565 nm) for in vivo tracking and injected intravenously in
6-OHDA-lesioned animals 3 weeks after brain surgery. Immunohis-
tochemistry of brain parenchyma for CD11b (expressed by micro-
glia and macrophages) from the rats killed 18 h after intravenous cell
transfusion showed Qdot565 nm-positive CD11b cells of polygo-
nal body shape in the striatum (Fig. 2D), confirming the infiltration
of peripheral CD163 cells to the brain.
CD163-targeted liposomes target the brain efficiently,
especially in the 6-OHDA model
The infiltration of peripheral CD163 cells into striatum en-
abled us to use the CD163 cells as mediators and/or tools to
modify the immune environment in the brain of 6-OHDA-
injected animals. To do so, we designed long-circulating lipo-
somes (LCLs), which were specifically targeted toward the CD163
receptor, by coating them with an anti-CD163 antibody (ED2
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clone). To assess the potential of the ED2-LCLs as drug carriers
and to evaluate biodistribution in the 6-OHDA model, we loaded
the ED2-LCLs with a 125I radiolabel and injected a single dose
intravenously (0.03 MBq) in 6-OHDA-lesioned animals and
sham rats 3 weeks after brain surgery. We followed the clearance
of the radioactive liposomes from the blood circulation, taking
regular blood samples for 2 h; thereafter, all animals were killed.
We collected brain, spleen, kidneys, heart, and a portion of the
Figure 1. CD163 cells in striatum.A,B, Representative photos of striatum immunostained against CD163 3weeks after surgery: the contralateral striatum received sham vehicle injection and
the ipsilateral side received37gof 6-OHDA (seeMaterials andMethods). CD163 cells in the contralateral striatumappearedmostly as rod-shaped cells associatedwith blood vessels (A,B),
whereas the 6-OHDA-lesioned side also exhibited numerous cells of polygonal shape in the parenchyma (B,B). C, Bar graph showing the average number of the two types of CD163 cells in
the striatumat1and3weeksafter surgery. Stereological quantificationof theCD163 cells in the6-OHDA-injected striatum3weeksafter surgery showsa significant increaseof total CD163 cells,
which was mainly driven by the increase of polygonal cells in the parenchyma. Values are mean SEM (n 5). Paired t test analysis: **p 0.001; ## p 0.01.
Figure 2. Tracking of ex vivo fluorescence-labeled CD163macrophages in the 6-OHDAmodel. A, Schematic representation of the experimental design: peritoneal macrophages were isolated
fromanaive rat and CD11b/CD163 cellswere FACS sorted. Thereafter, the cellswere ex vivo loadedwith Qdot565 and transfused intravenously to rats 3weeks after 6-OHDA lesion. The animals
were killed 24 h later and the brain processed for immunofluorescence (for details, seeMaterials andMethods).B, Representative FACS dot plot showing our selection strategy of CD11b/CD163
cell population: selectionof live cellswithFSCandSSCplot, doublets exclusionbasedonFCS-A/FCS-HandSSC-A/SSC-H, anda final gatebasedonCD11bandCD163expressionandon isotype controls.
C, Sort quality control of CD163/CD11b cells.D, Confocalmicroscopic analysis showing CD11b-containingQdot565 in the brain parenchyma suggesting infiltration of the ex vivo-loaded cells.
Scale bar, 6m applies to both.
Tentillier et al. • CD163-Targeted Dexamethasone Is Neuroprotective J. Neurosci., September 7, 2016 • 36(36):9375–9390 • 9379
liver to quantify the relevant quantity of
radioactivity and to calculate the reten-
tion of 125I-radiolabeled ED2-LCLs in
these different organs to compare distri-
bution and clearance in both 6-OHDA
and sham animals.
The 125I radiolabel was easily detect-
able in circulation soon after intravenous
injection, but decreased rapidly, with only
55% of the original dose detected in the
blood of 6-OHDA-injected rats after 20
min. Thereafter, the levels of radioactivity
remained almost stable in the blood until
2 h after injection (Fig. 3A). Interestingly,
the 6-OHDA-injected animals had always
the lowest radioactive readouts in circula-
tion at all time points tested, although
these were not significantly different from
sham (Fig. 3A). When we measured the
levels of radioactivity accumulated in tis-
sue after 2 h in selected tissues, we could
detect signal in all tissue analyzed, but the highest levels were
found in the liver, spleen, and kidneys (Fig. 3B). The high radio-
activity signal from the kidneys suggests an increased filtration of
liposome-free 125I, which correlates with the suggested increased
blood clearance in the 6-OHDA animals. Moreover, compared
with sham animals, increased radioactivity levels were also de-
tected in the brains of animals injected with 6-OHDA (Fig. 3C),
thus confirming the putative potential of these liposomes as ther-
apeutic tools for brain neurodegeneration. The uptake of radio-
active liposomes in the brain may be direct; that is, circulating
125I-radiolabeled ED2-LCLs are taken up by CD163-expressing
cells in the brain (likely PVM); or indirect, 125I-radiolabeled
ED2-LCLs are taken up by peripheral CD163 macrophages,
which are then recruited to the brain.
To further confirm the potential of CD163-targeted-LCLs to
reach the brain, we injected ED2-LCLs loaded with calcein intra-
venously in 6-OHDA-lesioned rats 1 and 3 weeks after brain
surgery. Subsequent analysis of the brains by confocal micros-
copy confirmed the uptake of ED2-LCLs in the brain tissue be-
cause calcein was observed in CD11b cells located in the brain
parenchyma (Fig. 4), further supporting the potential of CD163-
targeted LCLs as tools to target cells that reach the brain paren-
chyma. However, we cannot discard at this point that the CD163-
targeted LCLs loaded with calcein were taken up by CD163
PVM because some of the calcein-loaded cells appeared in close
proximity to blood vessels (Fig. 4A–D).
Experimental design: repeated injections of Dexa
encapsulated in liposomes targeted for the CD163
in the PDmodel
Our data showed that the CD163 peripheral cells are recruited
to the brain, where they infiltrate the striatum of rats in the
6-OHDA model, and that we could access the brain parenchyma
using this CD163 population by specific targeting via ED2-
LCLs. Therefore, we designed an experimental approach to use
CD163 cells to modify the neuroinflammatory process in stria-
tum and limit the pro-inflammatory environment in the neuro-
degenerative area. To do so, we loaded the CD163-targeted LCLs
with Dexa with the aim of modifying CD163 cells toward an
anti-inflammatory profile. We hypothesized that these modified
infiltrated CD163 cells would modulate the inflammatory pro-
cess associated with the 6-OHDA lesion in the striatal paren-
chyma, resulting in a neuroprotective effect in the nigrostriatal
dopaminergic system. Treatment was initiated 1 d before the
intracerebral 6-OHDA lesion, followed by treatment 3 times per
week for 3 weeks with Dexa-loaded-ED2-LCLs (Dexa 0.02 mg/
kg, 0.125 mM liposome solution; ED2-LCLs-Dexa). The follow-
ing were used as controls: (1) free phosphorylated-Dexa (Dexa 1
mg/kg; free Dexa), (2) Dexa loaded in nontargeted liposomes
(Dexa 0.02 mg/kg, 0.125 mM liposome solution; LCL-Dexa), and
(3) PBS-loaded liposomes (0.125 mM liposome solution, PBS,
0.15 M NaCl in 10 mM phosphate buffer, pH 7.4; PBS-LCL) in
three parallel groups. In a pilot experiment, we confirmed that
Figure 3. Biodistribution of 125I-radiolabeled-ED2-liposomes injected intravenously in the 6-OHDAmodel. A, Blood clearance of 125I-radiolabeled CD163-targeted-liposomes ( 125I-ED2-LCL) at
different time points after intravenous injection. Values are expressed as relative to signal at 2min.B, Mean and individual numbers of the radioactive signal from the 125I-ED2-LCL taken up in liver,
spleen, kidney, and heart. C, Mean and individual numbers of the radioactive signal from the 125I-ED2-LCL uptaken in brain. InB and C, values are expressed as a percentage of the injected dose per
gram of wet tissue. Values are mean SEM (n 3 sham and n 4 6-OHDA). Unpaired t test analysis: *p 0.05.
Figure 4. Peripheral injection of calcein-loaded ED2 liposomes in the 6-OHDA model. CD11b cells loaded with calcein were
found in the brain parenchyma, suggesting the uptake of liposomes by infiltrated CD163 cells and/or PVM. A–D, CD11b cells
loadedwith calcein in proximity of a blood vessel (likely a PVM). E–H, CD11b cell loadedwith calcein not clearly associatedwith
any blood vessel. Scale bar in A, 11m and applies to top row; scale bar in E, 5.5m and applies to bottom row.
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the 6-OHDA lesion was similar in PBS-loaded CD163-targeted
LCLs or PBS-untargeted LCLs (data not shown), therefore, we
used the last one as a control. The Dexa doses were chosen based
on our own previous study in rats, where we showed that 0.02 mg
of CD163-targeted Dexa/kg was as efficient as 1.0 mg of free
Dexa/kg at decreasing the LPS-induced TNF release (Graversen
et al., 2012).
Glucocorticoid side effect alleviation using liposome
encapsulation of Dexa
One of the major advantages of our approach is that, by targeting
specifically the CD163 population, the dose needed is substan-
tially lower than the normal Dexa doses used otherwise for anti-
inflammatory purposes; doses reported in the literature range
from 0.1 to 10 mg/kg (Quan et al., 2014). First, the barrier of
polyethylene glycol has been used to ensure that the LCLs are not
bound by opsonins and do not inhibit unspecific uptake in
phagocytic cells (Allen and Hansen, 1991). Second, we have
shown before that coating with polyethylene-glycol-linked anti-
CD163 antibodies or drug targeting via the ED2-anti-CD163 an-
tibody ensures fast uptake in CD163 cells (Etzerodt et al., 2012;
Graversen et al., 2012). All of these reduce the dose and therefore
the undesired side effects of a chronic treatment. To analyze the
side effects commonly observed with prolonged corticoid treat-
ments, we measured the endogenous serum cortisol level and
monitored body weight, which decreases in rodents after chronic
glucocorticoid treatment (Liu et al., 2011). In addition, we mea-
sured thymus size, a commonly used parameter in rodent studies
because it reflects the corticosteroid-mediated apoptosis of lym-
phocytes, dominating cells type of the thymus (Ben Rhouma and
Sakly, 1994; Cole et al., 2000). As expected, animals receiving free
Dexa showed a significant reduction in all three markers com-
pared with PBS-LCL animals, which did not received any Dexa
(p 0.001; Fig. 5). Animals receiving Dexa in targeted or untar-
geted liposomes were not different from PBS-LCL animals, con-
firming that the reduction of the dose achieved by the targeting
decreased the undesired side effects of the drug.
CD13-targeted Dexa alleviates motor defects
During the third week of treatment and after surgery, the animals
were tested for motor performance using the cylinder test. As a
result of the dopaminergic unilateral 6-OHDA neurodegenera-
tion, all animals showed a biased use of the ipsilateral paw versus
the lesioned ipsilateral one. However, animals that received ED2-
Figure 5. Treatment effect in systemic markers. Bar graphs show levels of cortisol in serum and (n 6–10; A) wet thymus tissue weight (n 5–6; B) after 3 weeks of treatment starting 1 d
before the 6-OHDA striatal injection. C, D, Body weight changes throughout the 3 weeks of treatment (C) and at the end point (D) (n 7). ED2-LCL-Dexa treatment was consistently significantly
different from free Dexa treatment. Values are mean SEM. One-way ANOVA followed by Tukey post hoc analysis: ***p 0.001; **p 0.01; *p 0.05.
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LCL-Dexa showed significantly better use
of the contralateral paw compared with
the LCL-PBS control animals. Free Dexa
treatment or untargeted Dexa-loaded li-
posomes did not result in a better motor
performance (Fig. 6) This supports a pro-





To analyze the status of the dopaminergic
nigrostriatal system, we measured the stri-
atal TH fiber innervation by densito-
metric analysis. All groups showed a
decrease of the dopaminergic innervation
in the ispsilateral striatum 3 weeks after
surgery. Although there was a slightly
higher density of TH fibers in the ED2-
LCL-Dexa, no significant difference was
found upon statistical analysis (one-way
ANOVA, F(3,20) 1.288 p 0.30; Fig. 7).
To analyze whether, despite the lack of protection of dopaminer-
gic terminals, we had a change in neuronal survival, we did ste-
reological quantification of the number of TH neurons in SN 3
weeks after surgery. The animals receiving ED2-LCL-Dexa had
indeed a significant higher number of surviving TH neurons
compared with those receiving free Dexa or control LCL-PBS
(Fig. 8A–L). Therefore, Dexa, when targeted to macrophages ex-
pressing CD163, could protect dopaminergic neurons, whereas
treatment with free Dexa or nontargeted LCL-Dexa did not
achieve similar neuroprotection.
Biochemical analysis of striatal DA metabolism
To analyze the effect of the treatment on DA metabolism, we
performed biochemical analysis of DA and metabolites in stria-
tum and SN 3 weeks after surgery by HPLC. We observed a sim-
ilar profile to that observed upon densitometric analysis of
dopaminergic terminals mentioned above, with the highest stri-
atal DA content in the animals receiving ED2-LCL-Dexa, even
though it did not reach significant difference (one-way ANOVA,
F(3,26)  2.420 p  0.089; Fig. 9A). The levels of HVA and
DOPAC and the turnover ratios indicated an increase in DA
turnover in the 6-OHDA-injected side compared with the con-
tralateral side in all groups except in the ED2-LCL-Dexa animals
(Fig. 9G–I). No change was observed in the DA, DOPAC, or HVA
content in SN and the turnover did not show any signs of signif-
icant changes (one-way ANOVA, F(3,22) 1.851, p 0.168; Fig.
9D–F, J–L).
CD163-targeted liposomes loaded with low doses of Dexa
inducedMHCII expression in nigral microglia
As expected, we observed a significant increase in the number of
microglia CD11b cells in the ipsilateral side in all groups (Fig.
10A). However, no difference of the ipsilateral microgliosis was
noticed between the CD163 liposomes loaded with Dexa and the
control treatments (Fig. 10B). Therefore, our treatment did not
avoid the proliferation (or recruitment) of microglia induced by
6-OHDA. We analyzed the expression of the CD68 phagocytic
marker in our samples. As described previously, we observed
upregulation of the protein in the ipsilateral SN, but no obvious
difference was found among groups (data not shown).
We also studied the phenotypic changes in activated microglia
by quantifying the number of MHCII-expressing microglia in a
single representative SN section. As expected, MHCII cells were
only seen occasionally in the contralateral side of the 6-OHDA
lesion at the level of the SN regardless of any treatment. However,
MHCII cells were densely stained with an activated hyperrami-
fied morphology on the ipsilateral side of the 6-OHDA lesion
(Fig. 11A–D). Animals that received ED2-LCL-Dexa treatment
had a significantly higher number of MHCII cells compared
with the free Dexa group, although animals receiving LCL-Dexa
also had elevated MHCII cells in SN (Fig. 11E). Interestingly,
when we plotted and analyzed neuronal dopaminergic survival
versus MHCIImicroglia in the SN, we observed a clear trend of
positive correlation (p 0.06). Indeed, animals showing an ele-
vated number of surviving TH cells also exhibited higher num-
bers of MHCIImicroglia in SN, but only in the ED2-LCL-Dexa
group, not in any of the other groups (Fig. 11F).
At the striatal level, all animals showed a robust upregulation
of MHCII expression in microglia. When we analyzed the area
covered by MHCII cells in striatal sections, we observed that
animals receiving ED2-LCL-Dexa and LCL-Dexa showed a more
widespread MHCII cell distribution (Fig. 12B,C) versus the
dense, delimitated area covered by MHCII cells in the control
groups (Fig. 12A,D).
Discussion
We report here that the CD163macrophage population signif-
icantly infiltrates the neurodegenerating striatal parenchyma in
the 6-OHDA PD model. We also show that neuroprotection can
be achieved by targeting the infiltrating CD163 cells using the
anti-inflammatory drug Dexa. To do so, we specially designed
liposomes targeted for the CD163 and loaded with glucocortico-
ids. We show that the CD163-targeted-liposomes reached the
brain parenchyma, which may occur directly (CD163 PVM) or
indirectly via CD163-recruited cells. Repeated intravenous in-
jections of these liposomes in the 6-OHDA rats resulted in better
motor performance and higher dopaminergic survival. This neu-
roprotection was observed mainly at the SN, where we also found
a significant microgliosis. However, the microglia response ap-
peared different, with a significantly higher number of MHCII
cells that correlated positively with the neuronal survival. Our
Figure 6. Motor performance after striatal 6-OHDA. Spontaneous forelimb usewas evaluated by the cylinder test after 3weeks
of treatment. Animals receiving ED2-LCL-Dexa showed better use of the contralateral paw than animals receiving LCL-PBS. Values
are expressed as use of the left paw as a percentage of the total: mean SEM (n 13–14). One-way ANOVA followed by Tukey
post hoc analysis: *p 0.05.
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data suggest that modifying the CD163 population by peripheral
injections of ED2-LCL loaded with Dexa induces a specific im-
mune response, which results in a distinctive microglial response
in the brain correlating with decreased dopaminergic cell death
and better motor performance.
We observed a distinguishable increase in the number of
CD163 cells in the lesioned striatum 3 weeks after 6-OHDA. This
was not just a consequence of blood–brain barrier damage during
surgery because sham surgery did not result in similar increases.
Previously, CD163 was defined as the scavenger receptor in mono-
cytes/macrophages responsible for the hemoglobin–haptoglobin
complex uptake (Kristiansen et al., 2001). CD163 changes during
inflammation and seems related to wound healing (Kowal et al.,
2011; Liu et al., 2015). As described, we found that CD163 expression
was normally confined to meningeal macrophages (data not shown)
and PVM (Polfliet et al., 2006). In healthy rat brain, only occasional
CD163 cells appear in the parenchyma; however, this was signifi-
cantly increased in the 6-OHDA-lesioned striatum. CD163
microglia-like cells were reported in certain brain lesion models,
although it is unclear whether these cells were of peripheral origin
(Zhang et al., 2012). To address whether peripheral CD163 cells
could be recruited to the brain parenchyma, we performed adoptive
transfer of CD163 peritoneal macrophages in 6-OHDA rats. Ex
vivo labeling of the CD163macrophages allowed us to follow them
in vivo and confirmed their infiltration from the periphery to the
brain parenchyma. This is consistent with previous reports docu-
menting infiltration of macrophages, but also T cells, in different
neurodegenerative models including PD (Kurkowska-Jastrzebska et
al., 1999; Kokovay and Cunningham, 2005; Simard et al., 2006; Ro-
driguez et al., 2007; Depboylu et al., 2012; Theodore and Maragos,
2015). These infiltrated macrophages may acquire later microglia
characteristics (Simard and Rivest, 2004). This recruitment into the
area of neurodegeneration seems to happen before cell death, but
persists after this occurs (Rodriguez et al., 2007). We saw a significant
Figure 7. Dopaminergic fiber innervation in striatum. A, Photomicrographs showing representative TH-immunostained striatal section in each group 3weeks after 6-OHDA lesion. B, Bar graph
illustrating the semiquantitativemeasurement of the TH densitometry expressed as the percentage of the contralateral side striatal; no significant changewas found between groups. Values are
mean SEM (n 6–9). One-way ANOVA followed by Tukey post hoc analysis.
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Figure8. Dopaminergic neuronal population in SN. A,D,G, J, Low-magnification photographs showing representative nigral sections immunostained for TH.B, C, E, F,H, I, K, L, Higher
magnification of SN from the naive (contralateral) and 6-OHDA (ipsilateral) sides of each section. Notice the higher density of TH neurons in the ipsilateral SN in the ED2-LCL-Dexa
animal compared with the LCL-PBS or free Dexa animals. L, Bar graphs illustrating the average number of surviving TH nigral neurons obtained by stereological quantification
expressed as a percentage of the contralateral side. Animals treated with ED2-LCL-Dexa showed higher number of TH neurons compared with the ones treated with LCL-PBS or free
Dexa. Scale bar in J, 12.5 mm and applies to A, D, G, and J; scale bar in L, 200m and applies to B, C, E, F, H, I, K, and L. Values are mean SEM (n 12–14). One-way ANOVA followed
by Tukey post hoc analysis: *p 0.05.
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increase of CD163 after 3 weeks, when cell death had occurred,
although our data may suggest that the infiltration could be initiated
as soon as 1 week aftersurgery. The role of the infiltrated cells is
unclear, but has been proposed to be deleterious based on their iNOS
expression (Kokovay and Cunningham, 2005) or protective based
on their GDNF expression (Rodriguez et al., 2007). In stroke, the
infiltrated cells express protein characteristics of both pro-
inflammatory and anti-inflammatory profiles, although their pre-
Figure 9. Analysis of DA and its metabolites and DA turnover rates. Levels of DA and its metabolites, DOPAC and HVA, were examined by HPLC in the striatum (A–C) and SN (D–F ) of animals
treated for 3weeks. All animals showed an overt decrease of DA in the lesioned ipsilateral striatum; ED2-LCL-Dexa animals exhibited the highest striatal DA content, but this did not reach significant
different (one-way ANOVA, F(3,26) 2420 p 0.089). The turnover of DAwas calculated as the DOPAC/DA (G, J ), HVA/DA (H,K ), and (DOPACHVA)/DA (I, L) and examined in the striatum (G–E)
and SN (J–L) of animals treated for 3 weeks with ED2-LCL-Dexa and control treatments. All animals showed a significant increase in all turnover ratios in the ipsilateral striatum except the
ED2-LCL-Dexa animals. No changes were observed in the SN. Values are mean SEM (n 6–8). Paired t test (contralateral vs ipsilateral) and one-way ANOVA (across groups): ***p 0.001;
**p 0.01; *p 0.05.
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Figure 10. Cd11b microglia population in the SN. A, Bar graph shows the average number of total cells obtained by stereological quantification of CD11b cells both in the
contralateral and ipsilateral SN after 3 weeks of treatment. Injection of 6-OHDA in the striatum induced a significant increase of CD11b population in the SN regardless of the
treatments. B, Bar graphs representing the CD11b population in the ipsilateral side expressed as a percentage of the contralateral side showing that no significant difference was
found. Values are mean SEM (n 8). Paired t test (in A) and one-way ANOVA followed by Tukey post hoc analysis (B).
Figure 11. MHCII microglia in SN. A–D, Low-magnification photos showing representative SN sections immunostained against MHCII from each group. High-power photomicro-
graphs showing insets illustrated in the top low-magnification photos. Notice the higher density of MHCII cells in the ipsilateral SN from the animal treated with ED2-LCL-Dexa
compared with the ones treated with LCL-PBS or free Dexa. E, Bar graph showing themean number of MHCII cells in ipsilateral SN expressed as a total number of cells per nigral section.
Animals treated with ED2-LCL-Dexa and untargeted LCL-Dexa showed an increased number of MHCII cells compared with the PBS-LCL control group. F, Positive correlation in between
TH neurons and MHCII cells in SN in ED2-LCL-Dexa-treated animals. Scale bar in D, 200 m and applies to high-power photomicrographs in A–D. Values are mean SEM (n
7–11). One-way ANOVA followed by Tukey post hoc analysis: ***p 0.001; **p 0.01; *p 0.05.
9386 • J. Neurosci., September 7, 2016 • 36(36):9375–9390 Tentillier et al. • CD163-Targeted Dexamethasone Is Neuroprotective
dominance varied with time (Miro-Mur et al., 2016; Wattananit et
al., 2016). In Alzheimer’s disease, infiltrated macrophages were re-
lated to plaque control (Simard et al., 2006). Intranasal delivery of
bone-marrow-derived stem cells resulted in their migration, mainly
to the 6-OHDA-lesioned side, accompanied by partial dopaminer-
gic neuroprotection (Danielyan et al., 2011). A similar approach in a
transgenic PD model resulted in migration of cells with the ability to
phagocyte -synuclein, also suggesting a protective role (Danielyan
et al., 2014). Therefore, the role of the infiltrated immune cells in
neurodegenerative disease seems complex, with both deleterious
and protective phenotypes occurring, probably based on local and
peripheral cues. In this context, the role of CD163 cells is unclear,
but its expression is generally considered a sign of an M2 alternative
phenotype (Van Gorp et al., 2010). In humans and monkeys,
CD163microglia-like cells appear in brain upon virus infections,
trauma lesions, and immune-related neurodegeneration (Borda et
al., 2008; Holfelder et al., 2011). CD163cells were observed close to
A plaques in Alzheimer’s disease patients’ brains, suggesting a role
for this population in protein aggregation-related neurodegenera-
tion (Zhang et al., 2011; Pey et al., 2014).
We observed that modulation of the immune response via ED2-
LCL results in significant protection of dopaminergic neurons and
improved motor behavior. Our hypothesis was that the inflamma-
tory event was actively participating in the neurodegenerative pro-
cess and therefore its modulation would result in protection. We
observed here a robust ipsilateral microgliosis 3 weeks after surgery,
as described previously (Marinova-Mutafchieva et al., 2009;
Virgone-Carlotta et al., 2013; Schlachetzki et al., 2014). CD68
expression suggests that microglial phagocytic activity precedes
neuronal death that might be detrimental for dopaminergic sur-
vival (Marinova-Mutafchieva et al., 2009). Accordingly, anti-
inflammatory strategies are neuroprotective in PD models, such as
minocycline or Dexa treatments in the MPTP model (Wu et al.,
2002; Kurkowska-Jastrzebska et al., 2004), as well as approaches de-
creasing pro-inflammatory mediators such as TNF (McCoy et al.,
2011) and IL-1beta (Koprich et al., 2008; Pott Godoy et al., 2008;
Tanaka et al., 2013). However, therapeutic strategies targeting pe-
ripheral macrophages have rarely been used before in PD. Ex vivo-
modified bone marrow stem cells or macrophages overexpressing
GDNF showed neuroprotection in the MPTP and the 6-OHDA
models (Biju et al., 2010; Zhao et al., 2014). Nano-formulated cata-
lase administered intravenously after acute MPTP intoxication re-
sulted in protection in SN (Brynskikh et al., 2010); in addition,
intravenous transfer of ex vivo-transfected macrophages with a cat-
alase plasmid DNA induced neuroprotection in the 6-OHDA model
(Haney et al., 2013). Intranasal delivery of bone-marrow-derived
stem cells has resulted in new macrophage-like cells in brain associ-
ated with neuroprotection (Danielyan et al., 2010; Danielyan et al.,
2011; Danielyan et al., 2014). Therefore, targeting peripheral macro-
phages seems to be a promising tool for neuroprotective therapies.
In our animals, we observed neuronal protection, but no sig-
nificant protection of the striatal terminals. This could be due to
the lesion design and the microglia/immune response time line.
Indeed, the 6-OHDA model is a retrograde neurodegenerative
model, in which the degeneration is initiated in the terminals and
progresses retrogradely toward the nigral cell body. Therefore,
the striatal fiber loss starts as soon as 6 h after injection and is
accompanied by a rapid and robust microgliosis (Walsh et al.,
2011; Stott and Barker, 2014). Although microglia change in pro-
file and protein expression is observed as early as 72 h in SN, the
microglia proliferation is delayed 1 week after lesion, at the same
time as neurons show the first sign of caspase-3 activation and
death (Walsh et al., 2011; Stott and Barker, 2014). This may result
in a better window for neuroprotection of the cell bodies using
our therapeutic strategy.
Remarkably, we observed microgliosis in SN despite the sig-
nificant dopaminergic survival, suggesting a modulation of the
immune response toward a neuroprotective type without
avoiding its proliferation or recruitment. Microglia, as macro-
phages, have different activation stages: pro-inflammatory, anti-
Figure 12. MHCII expression in striatum. Photos from striatal section immunostained against MHCII from representative animals of each group 3 weeks after striatal 6-OHDA lesions. Insets
indicate areas where the high-power photomicrographswere taken. The animals treatedwith ED2-LCL-Dexa and LCL-Dexa generally show a smaller area of denseMHCII cells at the needle track
area, composed of macrophages and or ramified microglia (B, C). Notice that the MHCII expression was not confined only to the core, but we observed MHCII cells spread throughout the
striatum (B, C, insets). LCL-PBS- and free-Dexa-treated animals normally showed a bigger but less dense core covered by MHCII expression associated with the injection area (A, D), but the
MHCII population seemed contained and did not spread through the striatal parenchyma (A, D, insets). Scale bar, 100m and applies to low-magnification photos.
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inflammatory, and repairing. The dynamic response of this
population will be determinant for the neuronal fate in PD
(Moehle and West, 2015). Others and we have shown previously
that microgliosis can occur in the absence of cell death and is
associated with neuroprotection (McCoy et al., 2006; Sanchez-
Guajardo et al., 2010; Sanchez-Guajardo et al., 2013b). In agree-
ment with our previous observations, we saw increased MHCII
expression in the animals in which we observed neuroprotection
(Sanchez-Guajardo et al., 2010; Sanchez-Guajardo et al., 2013b).
MHCII expression is elevated in microglia in PD patients and is
associated with -synuclein deposition (Croisier et al., 2005).
Remarkably, genetic variances related to the MHCII complex in
humans are correlated to PD, suggesting a key role for such pro-
teins (Hamza et al., 2010; Wissemann et al., 2013). Increased
MHCII has been correlated to neuroprotection upon CX3CL1
overexpression in the 6-OHDA model (Nash et al., 2015). Con-
versely, in an -synuclein viral-vector-based PD model, lack of
MHCII expression was protective; however, the MHCII knock-
out line used in the study presents a dramatic decrease of the
CD4 T-cell population, thus complicating the interpretation
(Madsen et al., 1999; Harms et al., 2013). MHCII is involved in
the presentation of antigens to T cells in adaptive immunity. The
adaptive immune system has been also linked to the 6-OHDA PD
model and, in the MPTP model, CD4T cells are proposed to be
essential in neurodegeneration (Brochard et al., 2009; Wheeler et
al., 2014; Theodore and Maragos, 2015). Interestingly, although
we also observed MHCII upregulation in untargeted LCL-Dexa
animals, they did not show neuronal protection, suggesting that
the targeting of the LCL to the CD163 population was key in
this therapeutic event. We do not yet know whether the differ-
ences reside in changes at the peripheral level or in brain. There-
fore, the observation requires further investigation to understand
its significance in neuroprotection.
Our results show that peripherally injected nanoparticles tar-
geted to the CD163 receptor can be used to modify the local CNS
microglia phenotype significantly and achieve neuroprotection
of dopaminergic neurons in a 6-OHDA model of PD. At this
point, we cannot discard a protection accomplished through sol-
uble mediators induced by peripheral changes. Nor we can reject
the possibility that the liposomes were taken up directly by
CD163 PVM in the brain. However, our data also suggest that a
CD163 macrophage population is involved in PD-like neurode-
generation, notably by infiltrating the brain parenchyma. The
exact role of these cells and the mechanisms of infiltration into
the brain parenchyma are still unclear. The results of our study
support the use of targeted glucocorticoids for the treatment of
chronic brain inflammation, but stress the importance of charac-
terizing the time course and the associated role of the CD163
cell population in the degenerative process.
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